Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome

Vibeke A Ingebrigtsen12*, Kjetil Boye13, Jahn M Nesland24, Arild Nesbakken26, Kjersti Flatmark15 and Øystein Fodstad12

Author Affiliations

1 Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway

2 Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, PO Box 1171, Blindern, N-0318 Oslo, Norway

3 Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway

4 Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway

5 Department of Gastroenterological Surgery, Norwegian Radium Hospital, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway

6 Department of Gastrointestinal Surgery, Oslo University Hospital – Aker, PO Box 4950, Nydalen, N-0424 Oslo, Norway

For all author emails, please log on.

BMC Cancer 2014, 14:602  doi:10.1186/1471-2407-14-602

Published: 20 August 2014

Abstract

Background

We have previously reported overexpression of the immunoregulatory protein B7-H3 in colorectal cancer and that nuclear expression predicted poor outcome in colon cancer patients. The present study was performed to examine the prognostic role of B7-H3 in an independent colorectal cancer cohort.

Methods

Using tissue microarrays from 731 colorectal cancer patients, tumour B7-H3 expression was assessed by immunohistochemistry. Associations with clinicopathological parameters and patient outcome were investigated.

Results

Nuclear expression of B7-H3 in cancer cells was present in 27% of the samples in the total study cohort, while cytoplasmic/membrane and stromal expression was seen in 86% and 77% of the samples, respectively. Nuclear B7-H3 had no prognostic relevance in the complete outcome cohort, neither in colon cancer patients. However, nuclear B7-H3 was significantly associated with reduced recurrence-free survival in TNM stage I colorectal cancer patients.

Conclusions

Overexpression of B7-H3 in colorectal cancer was confirmed, but in contrast to previous results, nuclear B7-H3 was not a strong prognostic biomarker in this cohort. The discrepancy might be related to the use of single-core tissue microarrays for detection of the heterogeneously expressed B7-H3, and the role of B7-H3 in colorectal cancer still needs further examination.

Keywords:
Colorectal cancer; Nuclear B7-H3; Prognostic biomarker; Tissue microarray